Esclerosis múltiple recurrente remitente en el sector público de salud de Chile. Descripción clínica de 314 pacientes
Cargando...
Fecha
2014
Profesor/a Guía
Facultad/escuela
Idioma
es
Título de la revista
ISSN de la revista
Título del volumen
Editor
Sociedad Médica de Santiago
Nombre de Curso
Licencia CC
Licencia CC
Resumen
Background: Immunomodulatory drugs (IMD), Interferon β1a, β1b and
glatiramer acetate are available in the Chilean public health system since June
2008 for patients with relapsing-remitting multiple sclerosis (RR-MS). Diagnostic
confirmation and programmed follow up of these patients is carried out
at a public national reference center. Aim: To describe the epidemiological and
clinical features of 314 patients evaluated in this center between 2008 and 2012.
Patients and Methods: Review of clinical records, to obtain information about
demographic background, medical history, expanded disability status scale of
Kurtzke (EDSS), multiple sclerosis functional composite (MSFC), intensity
fatigue scale of Krupp, Rao’s Brief Repeatable Battery of Neuropsychological
Tests (BNR-R) and anxious-depressive manifestations using Hamilton and Beck
questionnaires. Results: The ages of patients ranged from 12 to 63 years and 67%
were women. The initial symptoms were sensory disturbances in 20%, motor
alterations in 18% and optical neuritis in 16%. In 9% of patients, the disease
began with several manifestations. The EDSS was 4 or less in 73% of patients
and cognitive impairment was observed in 34%. Treatment failure during the
first and second years, occurred in 23 and 26% of patients, respectively. Male
gender, age under 40 and brainstem malfunction at the onset of disease, were
predictive of treatment failure during the second year. Conclusions: The features
of these patients are very similar to those reported abroad.
(Rev Med Chile 2014; 142: 559-566)
Key words: Disease progression; Immunomodulation; Multiple Sclerosisi,
Relapsin-Remitting
Notas
Indexación: Web of Science; Scielo.
Palabras clave
Disease progression; Immunomodulation; Multiple Sclerosisi, Relapsin-Remitting
Citación
Rev Med Chile 2014; 142: 559-566